Northwire Canada EditionSunday, August 9, 2026
Sign inSubscribe
Northwire
⌕
WHN 0.375 −2.6% LME 0.140 +3.7% AAUC 30.49 +5.3% GGM 0.040 +14.3% FDY 6.18 +3.2% MOG 0.640 +3.2% NEXM 3.20 +1.3% NCAU 0.330 +3.1% LUC 0.160 +0.0% BTR 0.140 +0.0% SMRV 0.200 −16.7% BIG 0.880 +3.5% URC 3.89 +0.0% ATY 0.250 −2.0% NRM 0.075 +7.1% WMS 0.040 +0.0% WHN 0.375 −2.6% LME 0.140 +3.7% AAUC 30.49 +5.3% GGM 0.040 +14.3% FDY 6.18 +3.2% MOG 0.640 +3.2% NEXM 3.20 +1.3% NCAU 0.330 +3.1% LUC 0.160 +0.0% BTR 0.140 +0.0% SMRV 0.200 −16.7% BIG 0.880 +3.5% URC 3.89 +0.0% ATY 0.250 −2.0% NRM 0.075 +7.1% WMS 0.040 +0.0%
Financings

Burcon Highlights Strong Year of Execution and Commercial Momentum in Shareholder Letter

By The Northwire Desk — AI Analysis Dec 15, 2025 · 08:01 BU · 1.71 BURCON NUTRASCIENCE CORPORATION J
BU · Price

Executive Summary

  • Burcon NutraScience projects 2025 revenue of $1‑3 million and reaffirms a target of >$10 million for calendar 2026.
  • The company is finalizing a financing supported by insiders and its manufacturing partner to fund production expansion, customer onboarding, and balance‑sheet flexibility.
  • Management highlights successful full‑scale validation of patented protein technologies and a pipeline of 200+ new customer projects.

Key Details

  • Revenue Guidance: 2025 calendar revenue expected in the range of $1 M – $3 M; 2026 target set at > $10 M.
  • Commercial Progress: Customers moving from evaluation to commercial purchase orders across pea, canola, and fava protein platforms; >200 new customer projects in the pipeline.
  • Technology Validation: Completed full‑commercial‑scale validation of patented protein technologies, reducing execution risk and confirming ability to deliver high‑performance ingredients at scale.
  • Manufacturing Partnership: Ongoing strategic partnership with RE ProMan LLC to scale production capacity for multiple protein categories.
  • Financing Intent: Company is finalizing a financing (details not disclosed) aimed at:
  • Supporting customer onboarding and accelerating conversion of ingredient sales.
  • Increasing operational throughput as demand scales.
  • Strengthening balance‑sheet flexibility during commercial expansion.
  • Investor Support: Financing strongly backed by insiders and the manufacturing partner, indicating confidence in growth strategy.
  • Strategic Outlook: Emphasis on clean‑label plant proteins meeting market demand for high purity, taste, and functionality; positioning for positive cash flow generation in the near term.

Notable Quotes

“Burcon has never been in a stronger position than it is today… we reaffirm our revenue target of more than $10 million for calendar 2026.” – Kip Underwood, Chief Executive Officer

All non‑material boilerplate, forward‑looking disclaimer text and contact information have been omitted for clarity.

Read the original news release →

More from BURCON NUTRASCIENCE CORPORATION J

Jun 26, 2026 · 16:21

Stonegate updates coverage on Burcon Nutrascience Corporation (BU) 4Q26

Earnings Jun 24, 2026 · 16:12

494% revenue jump overshadowed by $14.3M loss, negative equity, and costly insider debt; liquidity a red flag.

Earnings Jun 16, 2026 · 08:01

Commercial scaling accelerates, but negative equity and explicit capital calls keep the risk/reward skewed to the downside.

Production / Operations Apr 20, 2026 · 08:01

Burcon NutraScience Ramps Production Amidst Cash Burn Concerns

Production / Operations Feb 27, 2026 · 20:10

Burcon closes $2.75M second tranche of placement

Financings Feb 27, 2026 · 16:38

Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million

Financings